<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331695</url>
  </required_header>
  <id_info>
    <org_study_id>P040438</org_study_id>
    <nct_id>NCT00331695</nct_id>
  </id_info>
  <brief_title>Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery</brief_title>
  <official_title>Evaluation of the Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that the intramuscular administration of 17 alpha hydroxyprogesterones
      caproate allows to reduce the risk of preterm delivery, in 3 high risk populations defined by
      the association of an ultrasonographic cervical length egal and inferiority 26 mm between 20
      and 32 weeks of gestation and:

        -  either a first episode of preterm labor stopped by acute tocolysis;

        -  either a history of late miscarriage or premature delivery or uterine malformation or
           DES

        -  either a twin pregnancy. Therefore, a randomised, multicentre trial has been designed
           with initial stratification according to these three risk groups, opened with two
           parallel arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective

      To demonstrate that the intramuscular administration of 17 alpha - hydroxyprogesterones
      caproate allows to reduce the risk of preterm delivery, in 3 high risk populations defined by
      the association of an ultrasonographic cervical length 26 mm between 20 and 32 weeks of
      gestation and:

        -  either a first episode of preterm labor stopped by acute tocolysis;

        -  either a history of late miscarriage or premature delivery or uterine malformation or
           DES

        -  either a twin pregnancy. Experimental design Prospective, randomized, multicenter, trial
           with initial stratification according to three risk groups, opened with two parallel
           arms.

      The maximal duration for treatment will be 16 weeks for each included patient. The duration
      for inclusions will be 30 months. The duration for participation of each patient will be 10
      to 22 weeks. The foreseen inclusion period for this trial is from 06/01/2006 to 12/31/2008
      Description Two therapeutic strategies will be compared in each risk group and attributed by
      uniform randomisation.

      Arm A :IM injection of 17 alpha hydroxyprogesterones caproate, 500 mg, twice a week until 36
      W or until preterm delivery in high risk symptomatic group and high risk twin pregnancies
      group.

      IM injection of 17 alpha-hydroxyprogesterones caproate, 500 mg, once a week until 36 W or
      until preterm delivery in high risk asymptomatic group.

      Arm B :No treatment with 17 alpha-hydroxyprogesterones caproate. (usual management)
      Presentation : Progesterone retard Pharlon 500 mg Tolerance criteria

        -  nausea,vomiting,

        -  weakness
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interval between inclusion and delivery.</measure>
    <time_frame>during de study</time_frame>
    <description>Interval between inclusion and delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery rate &lt; 37 W, &lt; 34 W et &lt; 32 W,</measure>
    <time_frame>during the study</time_frame>
    <description>Preterm delivery rate &lt; 37 W, &lt; 34 W et &lt; 32 W,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations for preterm labor,</measure>
    <time_frame>during the study</time_frame>
    <description>Number of hospitalizations for preterm labor,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerclage performed at or after 20 weeks,</measure>
    <time_frame>during the study</time_frame>
    <description>Cerclage performed at or after 20 weeks,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal weight,</measure>
    <time_frame>during the study</time_frame>
    <description>Neonatal weight,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NICU transport</measure>
    <time_frame>during the study</time_frame>
    <description>NICU transport</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory distress syndrome,</measure>
    <time_frame>during the study</time_frame>
    <description>Respiratory distress syndrome,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia,</measure>
    <time_frame>during the study</time_frame>
    <description>Bronchopulmonary dysplasia,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis,</measure>
    <time_frame>during the study</time_frame>
    <description>Necrotizing enterocolitis,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leucomalacia,</measure>
    <time_frame>during the study</time_frame>
    <description>leucomalacia,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal death.</measure>
    <time_frame>during the study</time_frame>
    <description>neonatal death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">560</enrollment>
  <condition>Preterm Delivery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>17 alpha-hydroxyprogesterones caproate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 alpha-hydroxyprogesterones caproate</intervention_name>
    <description>17 alpha-hydroxyprogesterones caproate</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ultrasonographic cervical length 26 mm between 20 and 32 weeks of gestation and:

          -  either a first episode of preterm labor stopped by acute tocolysis

          -  either a history of late miscarriage or premature delivery or uterine malformation or
             DES;

          -  either a twin pregnancy.

        Exclusion Criteria:

          -  cervical dilatation &gt; 3 cm,

          -  chorioamnionitis,

          -  fetal distress,

          -  placenta praevia,

          -  abruptio placenta,

          -  preterm premature rupture of membranes,

          -  polyhydramnios,

          -  Twin-twin transfusion syndrome,

          -  IUGR,

          -  preeclampsia or hypertension,

          -  other pathology justifying a preterm delivery,

          -  epilepsy drugs

          -  participation to another therapeutic trial,

          -  any patient for whom informed consent cannot be obtained.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick ROZENBERG, MD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHI Poissy st Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Poissy St Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rozenberg P, Rudant J, Chevret S, Boulogne AI, Ville Y. Repeat measurement of cervical length after successful tocolysis. Obstet Gynecol. 2004 Nov;104(5 Pt 1):995-9.</citation>
    <PMID>15516390</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>May 6, 2011</last_update_submitted>
  <last_update_submitted_qc>May 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Christophe AUCAN</name_title>
    <organization>Department of Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Progesterone</keyword>
  <keyword>Preterm delivery</keyword>
  <keyword>Preterm labor</keyword>
  <keyword>Cervical length</keyword>
  <keyword>ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

